Related Experiment Videos
Microscopic polyarteritis: presentation, pathology and prognosis
Abstract:
We have described 34 patients with microscopic polyarteritis, all of whom had clinical evidence of a systemic small vessel vasculitis predominantly affecting the skin and musculoskeletal systems accompanied by a focal necrotising glomerulonephritis with renal impairment. Thirty three patients received immunosuppressive treatment, comprising prednisolone, azathioprine, cyclophosphamide and plasma exchange in various combinations. The five-year actuarial patient and kidney survival rates were 65 and 55 per cent respectively, suggesting that aggressive immunosuppressive therapy in these patients is beneficial.
Insights
Aggressive immunosuppressive therapy, including prednisolone and cyclophosphamide, improved survival rates in patients with microscopic polyarteritis, a systemic small vessel vasculitis. Five-year patient and kidney survival rates were 65% and 55% respectively.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Microscopic polyarteritis is a systemic small vessel vasculitis.
- Patients often present with skin and musculoskeletal symptoms.
- Renal impairment due to focal necrotising glomerulonephritis is common.
Purpose of the Study:
- To evaluate the efficacy of immunosuppressive therapy in patients with microscopic polyarteritis.
- To determine patient and kidney survival rates in treated patients.
Main Methods:
- Retrospective analysis of 34 patients with microscopic polyarteritis.
- Treatment regimens included prednisolone, azathioprine, cyclophosphamide, and plasma exchange.
- Actuarial survival rates were calculated over five years.
Main Results:
- Thirty-three patients received immunosuppressive treatment.
- Five-year patient survival rate was 65%.
- Five-year kidney survival rate was 55%.
Conclusions:
- Aggressive immunosuppressive therapy appears beneficial for patients with microscopic polyarteritis.
- Treatment can improve both patient and renal outcomes.
- Further research into optimal treatment strategies is warranted.